Travere Therapeutics Inc (TVTX, Financial) is set to release its Q3 2024 earnings on October 31, 2024. The consensus estimate for Q3 2024 revenue is $59.63 million, and the earnings are expected to come in at -$0.70 per share. The full year 2024's revenue is expected to be $223.32 million and the earnings are expected to be -$3.80 per share. More detailed estimate data can be found on the Forecast page.
Travere Therapeutics Inc (TVTX, Financial) Estimate Trends
Over the past 90 days, revenue estimates for Travere Therapeutics Inc (TVTX) for the full year 2024 have increased from $216.20 million to $223.32 million, and for 2025, estimates have risen from $327.34 million to $342.95 million. Earnings estimates, however, have shown mixed trends; for the full year 2024, they have slightly declined from -$3.79 per share to -$3.80 per share, while for 2025, they have improved from -$1.69 per share to -$1.53 per share.
Travere Therapeutics Inc (TVTX, Financial) Reported History
In the previous quarter of June 30, 2024, Travere Therapeutics Inc's (TVTX) actual revenue was $54.12 million, which beat analysts' revenue expectations of $50.17 million by 7.87%. Travere Therapeutics Inc's (TVTX) actual earnings were -$0.91 per share, which missed analysts' earnings expectations of -$0.88 per share by -3.64%. After releasing the results, Travere Therapeutics Inc (TVTX) was down by -2.60% in one day.
Travere Therapeutics Inc (TVTX, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 15 analysts, the average target price for Travere Therapeutics Inc (TVTX) is $22.67 with a high estimate of $41 and a low estimate of $12. The average target implies an upside of 23.39% from the current price of $18.37.
Based on GuruFocus estimates, the estimated GF Value for Travere Therapeutics Inc (TVTX, Financial) in one year is $31.25, suggesting an upside of 70.11% from the current price of $18.37.
Based on the consensus recommendation from 16 brokerage firms, Travere Therapeutics Inc's (TVTX, Financial) average brokerage recommendation is currently 1.8, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
